Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Feasibility and safety of early discharge in ND AML following intensive induction therapy

Rory Shallis • 11 Dec 2023
ASH 2023
Leukemia CPX-351

Rory Shallis, MD, Yale Cancer Center, New Haven, CT, shares outcomes for patients discharged before absolute neutrophil count (ANC) recovery following intensive induction therapy for newly diagnosed (ND) acute myeloid leukemia (AML). Those who met specific criteria could be safely discharged early without detriment to overall survival (OS), although this came with a slight increase in infection rates. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultancy: Bristol Myers Squibb, Curio Science, Servier, Rigel, Gilead Sciences

More from Rory Shallis

The BLAST AML-2 trial: the addition of pembrolizumab to azacitidine and venetoclax in AML
2:32
The BLAST AML-2 trial: the addition of pembrolizumab to azacitidine and venetoclax in AML
Rory Shallis • 9 Dec 2024
Impact of time from diagnosis to treatment in patients with AML treated with HMA plus venetoclax
2:23
Impact of time from diagnosis to treatment in patients with AML treated with HMA plus venetoclax
Rory Shallis • 9 Dec 2024
Association between BMI and outcomes for patients with AML treated with HMA plus venetoclax
1:58
Association between BMI and outcomes for patients with AML treated with HMA plus venetoclax
Rory Shallis • 9 Dec 2024
The outcomes of intensive treatment for patients with AML who have failed venetoclax-based therapy
2:22
The outcomes of intensive treatment for patients with AML who have failed venetoclax-based therapy
Rory Shallis • 9 Dec 2024

Related Videos

Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
1:45
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
Celso Arrais • 17 Oct 2026
Insights into the current CLL treatment algorithm and emerging research directions
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
1:21
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
Richard Rosenquist • 17 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals